Huang Zhu

Dr. Zhu has over a decade of experience in developing stem cell derived therapeutics and joined Shoreline Biosciences since January 2021, where he built a talented and nimble research team, oversees iPSC derived NK (iNK) cell platform development, initiation of therapy programs, and external partnerships. Prior to joining Shoreline, Dr. Zhu was focused on developing cord blood derived, allogenic NK cell product at Takeda, Cell Therapy. Previously, he had held multiple research positions of increasing responsibilities at Eli Lilly and Company China R&D center.

His studies as a post-doctoral fellow were the first to uncover the crucial function of cytokine-inducible SH2 containing protein (encoded by gene CISH), a critical negative regulator of NK function in human iNK cells. CISH knock out iNK cell is now the core cell engineer of Shoreline’s iNK cell products with enhanced durability and activity for optimal performance in fighting against cancers. In addition, he also led the development of high-affinity, non-cleavable CD16 iNK cell product (hnCD16-iNK) to augment antibody-dependent cellular cytotoxicity (ADCC) which is now in clinical development, showing very promising clinical efficacies in patients with B cell lymphoma.

Dr. Zhu has published over 20 papers in prestigious scientific journals. He received a B.A. in Biochemistry from Tianjin University, a Ph.D. in Molecular Biology and Developmental Biology from Shanghai Jiao Tong University, China, and was a Postdoctoral Fellow at University of California, San Diego, California.